<DOC>
	<DOC>NCT03070340</DOC>
	<brief_summary>The purpose of this study is to compare the diagnostic accuracy of breast magnetic resonance imaging (MRI) and contrast enhanced digital mammography (CEDM) in assessing the residual disease extent in patients who have completed neoadjuvant therapy (NAT).</brief_summary>
	<brief_title>Comparison of MRI and CEDM to Evaluate Treatment Response Before Surgery</brief_title>
	<detailed_description />
	<criteria>Any women who has completed neoadjuvant therapy for breast cancer and is scheduled for a postNAT breast MRI and mammogram Surgery (mastectomy or BCT) scheduled within 60 days of the MRI Women who have a contraindication to the intravenous use of iodinated contrast agent (i.e., allergy to iodinated contrast or severely impaired renal function with a creatinine level &gt; 1.3 or eGFR â‰¥45) Known allergic reaction to gadolinium; patient may be eligible if the referring physician determines that the MRI is medically necessary and if the patient is willing to undergo premedication for contrast allergy Pregnant women Male patients Presence of non MR compatible metallic objects or metallic objects that, in the opinion of the radiologist, would make MRI a contraindication Known or suspected renal impairment. Requirements for GFR prior to MRI as determined by local site standard practice Women who have already had their standard of care postNAT mammogram and/or breast MRI</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>mastectomy</keyword>
	<keyword>breast MRI</keyword>
	<keyword>contrast enhanced mammography</keyword>
	<keyword>CEDM</keyword>
	<keyword>17-045</keyword>
</DOC>